Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay

AIM: The 21-gene recurrence score (RS) predicts a clinical benefit of chemotherapy for individuals with ER-positive/HER2-negative breast cancer. Using in vitro chemoresponse assay, we compared the chemosensitivity according to RS in these patients. METHOD: Among the patients with Oncotype Dx assay,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Sung Gwe, Bae, Soong June, Yoon, Changik, Cha, Yoon Jin, Lee, Hak Woo, Lee, Seung Ah, Jeong, Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695596/
https://www.ncbi.nlm.nih.gov/pubmed/29117208
http://dx.doi.org/10.1371/journal.pone.0187679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695596/
https://www.ncbi.nlm.nih.gov/pubmed/29117208
http://dx.doi.org/10.1371/journal.pone.0187679

Ejemplares similares